Trial Radar IA
Lo studio clinico NCT03936478 (MAPBI) per Cancro al seno, DCIS, LCIS è in arruolamento. Consulti la vista a schede del Radar degli Studi Clinici e gli strumenti di scoperta IA per tutti i dettagli. Oppure, ponga pure una domanda qui.
Un studio corrisponde ai criteri del filtro
Vista a schede
Torna alla ricerca

Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer (MAPBI) Fase II 30 Innovativo

In arruolamento
I dettagli dello studio clinico sono disponibili principalmente in inglese. Tuttavia, Trial Radar IA può essere d'aiuto! Basta cliccare su 'Spiega lo studio' per visualizzare e discutere le informazioni sullo studio nella lingua selezionata.
La sperimentazione clinica NCT03936478 (MAPBI) è uno studio interventistico di Fase II volto a esaminare il trattamento per Cancro al seno, DCIS, LCIS, attualmente in arruolamento. Avviato il 16 maggio 2022, prevede di arruolare 30 partecipanti. Sotto la guida di l'Università del Wisconsin-Madison, dovrebbe concludersi entro il 1 gennaio 2031. I dati più recenti da ClinicalTrials.gov sono stati aggiornati l'ultima volta il 1 agosto 2025.
Sommario breve
This trial will investigate a novel 3-fraction radiation regimen for participants undergoing breast-conserving therapy (BCT) for early breast cancer that will: 1) significantly reduce the duration of treatment and can be completed in one-week (5 working days) and 2) MRI-guided radiotherapy (MRIdian) would limit the volume of normal tissue radiated and therefore resultant toxicity. The hypothesis is that 3-fraction ra...Mostra di più
Titolo ufficiale

A Phase II Study of Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer (MAPBI)

Patologie
Cancro al senoDCISLCIS
Altri ID dello studio
  • MAPBI
  • UW18099
  • 2019-0322 (Altro identificativo) (Institutional Review Board)
  • SMPH\HUMAN ONCO\HUMAN ONCO (Altro identificativo) (UW Madison)
  • A533300 (Altro identificativo) (UW Madison)
  • NCI-2019-03111 (Identificativo del registro) (NCI Trial ID)
  • Protocol Version 5/10/2021 (Altro identificativo) (UW Madison)
Numero NCT
NCT03936478
Data di inizio (effettiva)
2022-05-16
Ultimo aggiornamento pubblicato
2025-08-01
Data di completamento (stimata)
2031-01
Arruolamento (previsto)
30
Tipo di studio
Interventistico
FASE
Fase II
Stato
In arruolamento
Parole chiave
cosmesis
cosmetic
breast-conserving therapy
Scopo principale
Trattamento
Allocazione
N.D.
Modello di intervento
A gruppo singolo
Mascheramento
Nessuno (studio in aperto)
Bracci / Interventi
Gruppo/Braccio di partecipantiIntervento/Trattamento
Sperimentale8.2 Gy Radiation Therapy
Accelerated partial breast irradiation using 3 x 8.2 Gy to the lumpectomy cavity with a 3mm PTV margin. Treatment duration will be 5-6 days and treatments will be on alternative weekdays, with a minimum interval of 40 hours between subsequent fractions.
MRIdian Radiation Treatment Unit
partial breast irradiation using 3 x 8.2 Gy to the lumpectomy cavity with a 3mm planning tumor volume (PTV) margin
Esito primario
Misure di esitoDescrizione della misuraArco temporale
Physician Reported Cosmesis: 1-year
The Harvard Cosmesis Scale will be used to report cosmesis at 1 year post treatment. The physician will report how the breast looks relative to original appearance or untreated breast (excellent, good, fair, poor). The physician answers 9 questions on a scale of 0-2 where 0 is none, 1 is present but does not affect cosmesis, 2 is present and affects cosmesis. Scoring is objective with lower scores indicating improved conditions.
up to 1-year
Esito secondario
Misure di esitoDescrizione della misuraArco temporale
Participant Quality of Life: BCTOS Survey
Participant Quality of Life will be assessed prior to starting treatment, at end of radiotherapy (RT), 4 weeks post RT, 6 months post RT, 12 months post RT and yearly through 5 years by collecting measures from three scales.The Breast Cancer Treatment Outcomes Scale (BCTOS) is a 22-item scale scored 1-4 where 1 is none, 2 is slight, 3 is moderate, and 4 is large. Total score ranges from 22-88 where lower scores indicated better outcomes.
up to 5 years
Participant Quality of Life: Convenience of Care Scale
Participant Quality of Life will be assessed prior to starting treatment, at end of radiotherapy (RT), 4 weeks post RT, 6 months post RT, 12 months post RT and yearly through 5 years by collecting measures from three scales. The Convenience of Care scale is an 8-item scale scored 0 (not at all) to 10 (a lot). The total score ranges from 0-80 where lower scores indicate less disruptive interventions.
up to 5 years
Participant Quality of Life: MOS SF-36 Survey
Participant Quality of Life will be assessed prior to starting treatment, at end of radiotherapy (RT), 4 weeks post RT, 6 months post RT, 12 months post RT and yearly through 5 years by collecting measures from three scales.The Medical Outcomes Study Short Form - 36 (MOS SF-36) Vitality scale measures how a participant has felt in the last 4 weeks. 4-items are scored from 1-5 where 1 is all of the time and 5 is none of the time. 4-items are scored from 0 (no pain) to 10 (pain as bad as you can imagine). Total score ranges from 4-60 where lower scores indicate increased vitality.
up to 5 years
Physician Reported Cosmesis: 3-year
The Harvard Cosmesis Scale will be used to report cosmesis at 1 year post treatment. The physician will report how the breast looks relative to original appearance or untreated breast (excellent, good, fair, poor). The physician answers 9 questions on a scale of 0-2 where 0 is none, 1 is present but does not affect cosmesis, 2 is present and affects cosmesis. Scoring is objective with lower scores indicating improved conditions.
up to 3 years
Physician Evaluated Fat Necrosis
Fat necrosis will be assessed prior to treatment, at 6 months post RT, at 12 months post RT, and yearly through 5 years, graded as follows: Grade 0 is no fat necrosis, Grade 1 is Asymptomatic fat necrosis (only radiologic and/or cytologic findings), Grade 2 is Symptomatic fat necrosis not requiring medication (palpable mass with or without mild pain), Grade 3 is Symptomatic fat necrosis requiring medication (palpable mass with significant pain), Grade 4 is Symptomatic fat necrosis requiring surgical intervention.
up to 5 years
Acute Radiation Toxicity
The NCI's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 will be used to identify the type and to grade the severity of acute toxicities. Acute toxicities will be scored from the start of radiation to 90 days after completion of radiotherapy and late toxicities will be scored \> 90 days from completion of radiation therapy.
up to 90 days from completion of radiation therapy
Late Radiation Toxicity
The NCI's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 will be used to identify the type and to grade the severity of late toxicities.
up to 5 years
Ipsilateral Breast Tumor Recurrence (IBTR)
Defined as evidence of invasive or in situ breast cancer (except LCIS) in the ipsilateral breast. Participants who develop clinical evidence of tumor recurrence in the remainder of the ipsilateral breast must have a biopsy of the suspicious lesion to confirm the diagnosis with documentation of the location.
up to 5 years
Ipsilateral Regional Nodal Recurrence
Defined as the development of tumor in the ipsilateral internal mammary, ipsilateral supraclavicular, ipsilateral infraclavicular and/or ipsilateral axillary nodes, as well as the soft tissue of the ipsilateral axilla, after operation.
up to 5 years
Disease Free Survival (DFS)
Disease free survival (DFS) defined as the time from start of radiation to the time of documented recurrent disease in the ipsilateral breast or regional nodes (supraclavicular, axillary or internal mammary) or distant sites (e.g. bone, liver, lung or brain).
up to 5 years
Overall Survival (OS)
Overall survival (OS) defined as the time from start of radiation to death from any cause.
up to 5 years
Assistente alla partecipazione
Criteri di eleggibilità

Età idonea
Adulto, Adulto anziano
Età minima
40 Years
Sessi idonei
Femmina

For all participants

  • Participants should have no contraindications to undergo MRI scan as part of radiotherapy planning and treatment.
  • Lumpectomy cavity must be clearly visible on CT and MRI scan at radiotherapy simulation.
  • Pregnancy test negative in women of child bearing potential (WOCBP).
  • The participant must consent to be in the study and must have signed an approved consent form conforming with institutional guidelines.
  • Participants with a history of non-breast malignancies are eligible if they have been disease-free for 5 or more years prior and are deemed by their physician to be at low risk for recurrence. Participants with the following cancers are eligible if diagnosed and treated within the past 5 years: carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinoma of the skin.

For participants with Invasive Carcinoma

  • Suitable:

    • Age: >=50 years

      • Margins: Negative by at least 2 mm
      • T Stage: Tis or T1

  • Cautionary:

    • Age: 40-49 years

      • Margins: Negative by at least 2 mm
      • T Stage: Tis or T1 OR

    • Age: >=50 years IF participant has at least 1 of the pathologic factors below and does not have any "unsuitable" factors (below)

      • Pathologic Factors:

        • Size 2.1-3.0 cm (size of the invasive component)
        • T2
        • Close margins (<2 mm)
        • Limited/focal Lymphovascular Space Invasion (LVSI)
        • ER (-)
        • Clinically unifocal with total size 2.1-3.0 cm (Microscopic multifocality allowed, provided the lesion is clinically unifocal (a single discrete lesion by physical examination and ultrasonography/mammography) and the total lesion size (including foci of multifocality and intervening normal breast parenchyma) falls between 2.1 and 3.0 cm).
        • Invasive lobular histology
        • Extensive Intraductal Component (EIC) <=3 cm

For participants with DCIS

  • Suitable Criteria, DCIS allowed if all of the following are met:

    • Screen-detected
    • Low to intermediate nuclear grade
    • Size <=2.5 cm
    • Resected with margins negative at >=3mm OR

  • Cautionary Criteria:

    • Pure DCIS <=3 cm if "suitable" criteria not fully met

  • Men are not eligible for this study.
  • BRCA1/2 mutation positivity.
  • Age < 40 years (American Society for Radiation Oncology (ASTRO) Unsuitable Criteria).
  • Positive resection margins on post operative pathology(ASTRO Unsuitable Criteria).
  • Palpable or radiographically suspicious ipsilateral or contralateral axillary, supraclavicular, infraclavicular, or internal mammary nodes, unless there is histologic confirmation that these nodes are negative for tumor.
  • Suspicious micro calcifications, densities, or palpable abnormalities (in the ipsilateral or contralateral breast) unless biopsied and found to be benign.
  • Non-epithelial breast malignancies such as sarcoma or lymphoma.
  • Proven multicentric carcinoma (invasive cancer or DCIS) (ASTRO Unsuitable Criteria).
  • Pure DCIS >3 cm in size (ASTRO Unsuitable Criteria).
  • Presence of extensive intraductal component >30mm (ASTRO Unsuitable Criteria).
  • Paget's disease of the nipple.
  • History of previous invasive breast cancer, DCIS, synchronous bilateral invasive or non-invasive breast cancer. (Participants with a history of LCIS treated by surgery alone are eligible.)
  • Surgical margins that cannot be microscopically assessed or are positive at pathologic evaluation.
  • Concurrent therapy with any hormonal agents such as raloxifene (Evista®), tamoxifen, Aromatase Inhibitors or other selective estrogen receptor modulators (SERMs), either for osteoporosis or breast cancer prevention or neoadjuvant therapy.
  • Breast implants.
  • Prior breast or thoracic radiotherapy for any condition or treatment plan that includes regional nodal irradiation.
  • Collagen vascular disease, specifically dermatomyositis with a creatinine phosphokinase level above normal or with an active skin rash, systemic lupus erythematosus, or scleroderma.
  • Pregnancy or lactation at the time of treatment. Women of reproductive potential must agree to use an effective non-hormonal method of contraception during therapy.
  • Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the participant from meeting the study requirements.
University of Wisconsin, Madison logoUniversità del Wisconsin-Madison
Contatti principali dello studio
Contatto: Cancer Connect, 800-622-8922, [email protected]
1 Centri dello studio in 1 paesi

Wisconsin

University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, 53705, United States
Cancer Connect, Contatto, 800-622-8922, [email protected]
Bethany Anderson, MD, Investigatore principale
In arruolamento